Reaction

White Blood Cell Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,650 reports · 66 co-occurring drugs

As of the last recalculation, White Blood Cell Disorder appears in 2,650 FAERS reports alongside 66 co-occurring drug terms. The strongest observed disproportionality signal is BRENTUXIMAB VEDOTIN (PRR 15.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Brentuximab Vedotin	20	15.4	15.5
Ribociclib	57	14.5	14.5
Palbociclib	134	11.6	11.6
Dimenhydrinate	15	11.1	11.1
Fulvestrant	43	10.4	10.4
Alemtuzumab	25	10.2	10.3
Anastrozole Tablets	26	9.6	9.6
Eptinezumab-Jjmr	11	9.5	9.5
Hydroxyurea	25	9.4	9.4
Acalabrutinib	14	9.1	9.1
Nilotinib	33	8.9	8.9
Filgrastim	40	8.5	8.5
Ruxolitinib	74	8.3	8.3
Ifosfamide	22	8.1	8.1
Trimethoprim	12	8.0	8.0
Anastrozole	36	7.8	7.8
Niraparib	21	7.5	7.5
Azacitidine	27	7.2	7.2
Eculizumab	48	7.0	7.1
Prochlorperazine Maleate	8	6.8	6.8
Letrozole Tablets	41	6.8	6.8
Diroximel Fumarate	10	6.6	6.6
Venetoclax	49	6.3	6.4
Phenytoin	16	6.1	6.1
Peginterferon Alfa-2A	39	5.7	5.7
Letrozole	44	5.7	5.7
Piperacillin Sodium,Tazobactam Sodium	19	5.7	5.7
Doxorubicin Hydrochloride	23	5.6	5.6
Fingolimod Hcl	60	5.6	5.6
Pegfilgrastim	67	5.4	5.4
Ibrutinib	52	5.1	5.1
Cytarabine	38	5.0	5.0
Cisplatin	48	4.9	4.9
Dalfampridine	44	4.9	4.9
Temozolomide	13	4.9	4.9
Azacitidine For	11	4.8	4.8
Acyclovir	67	4.7	4.7
Pomalidomide	59	4.6	4.6
Avapritinib	7	4.5	4.6
Lenalidomide	222	4.4	4.4
Bosutinib	5	4.4	4.4
Dasatinib	20	4.3	4.3
Etoposide	39	4.2	4.2
Dimethyl Fumarate	63	4.1	4.1
Vincristine Sulfate	15	4.0	4.0
Gemcitabine	20	4.0	4.0
Doxorubicin	44	3.9	3.9
Clozapine	60	3.8	3.8
Imatinib Mesylate	13	3.7	3.7
Siponimod	4	3.5	3.5
Eltrombopag Olamine	10	3.4	3.4
Olaparib	9	3.4	3.4
Naltrexone	13	3.3	3.3
Gemcitabine Hydrochloride	22	3.3	3.3
Polatuzumab Vedotin	4	3.2	3.2
Lacosamide	15	3.2	3.2
Teriflunomide	18	3.1	3.1
Ribavirin	25	3.1	3.1
Irinotecan Hydrochloride	5	3.1	3.1
Blinatumomab	4	3.0	3.0
Daratumumab	15	3.0	3.0
Voclosporin	3	2.7	2.7
Sarilumab	9	2.7	2.7
Abemaciclib	6	2.4	2.4
Trifluridine And Tipiracil	3	2.2	2.2
Relugolix	6	2.0	2.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.